Harsh and Sweet Sensations Predict Acute Liking of Electronic Cigarettes, but Flavor Does Not Affect Acute Nicotine Intake: A Pilot Laboratory Study in Men.

Plain-language guide to PMID 33047127 (2021): pilot randomized controlled trial of Therapeutic nicotine (patch, non-peptide).

Key Facts

PMID: 33047127
Journal: Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco
Year: 2021
Study type: Randomized Controlled Trial
Authors: Baker AN et al. (4 authors)
DOI: 10.1093/ntr/ntaa209

What This Study Did, in Plain Language

What Was Tested

The paper reports a study of Therapeutic nicotine (patch, non-peptide), published as a randomized controlled trial.

Adolescent vaping rates in the United States have nearly doubled in the past year.

Unlike combustible tobacco, added flavors are not currently regulated for some types of electronic cigarette products.

Who Took Part

PubMed indexes the participants as teenagers, young adults, adults and middle-aged adults, men only.

After the first puff, participants rated sensations (sweetness, bitterness, coolness, harshness/irritation) on general labeled magnitude scales (gLMS) and rated overall liking on a generalized hedonic scale.

Once the 10-minute session ended, participants made another set of ratings.

How the Study Was Run

The researchers set it up as a randomized and pilot study.

The participants were allocated by chance, so the Therapeutic nicotine (patch, non-peptide) group and the comparison group should start out alike.

It is described as a pilot, a small early test of whether a larger Therapeutic nicotine (patch, non-peptide) study would be practical.

They completed several questionnaires, and vaped ad libitum for 10 minutes.

What Was Measured

PubMed files the paper under topics including Electronic Nicotine Delivery Systems, Flavoring Agents, Laboratories, Nicotine, Pilot Projects, Sensation and Taste.

What This Means in Plain Language

The paper is a randomized and pilot study of Therapeutic nicotine (patch, non-peptide).

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2021 (Nicotine & tobacco research : official journal of the Society for Research on Nicotine and Tobacco), a journal based in England.

More context: the Therapeutic nicotine (patch, non-peptide) compound page, all human trials.

Our Notes on the Compound

Therapeutic nicotine (patch, non-peptide): Pure nicotine as a signaling tool, separated from smoking and vaping.

Therapeutic nicotine (patch, non-peptide) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.